Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Apr;22(2):128-133.
doi: 10.1016/j.jaapos.2017.12.005. Epub 2018 Mar 14.

Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study

David Morrison  1 , James Shaffer  2 , Gui-Shuang Ying  2 , Gil Binenbaum  3 ; G-ROP Study Group
Collaborators, Affiliations
Comparative Study

Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study

David Morrison et al. J AAPOS. 2018 Apr.

Abstract

Purpose: To determine the prevalence of treatment-related ocular complications and disease progression following treatment for retinopathy of prematurity (ROP).

Methods: This was a retrospective cohort study of eyes treated for ROP at 29 North American neonatal intensive care units in the Postnatal Growth and ROP (G-ROP) Study. Data from the time of treatment through 15 months were abstracted from medical records by certified data collectors. Treatment-related complication (cataract, hyphema, glaucoma, corneal abrasion/opacity), and disease-progression (retinal fold, dragging, or stage 4 or 5 detachment) were calculated by treatment modality. Vitreous hemorrhage was classified separately, because it can relate to treatment or disease progression.

Results: Of 7,483 infants included in the study, 1,004 eyes (512 infants) underwent ROP treatment: 970 eyes received laser as initial therapy; 34 eyes received intravitreal bevacizumab (IVB). Median follow-up after treatment was 18 weeks. Overall, one or more complications occurred in 2.6% (95% CI, 1.8%-3.8%) laser treated eyes and no (0%; 95% CI, 0.0%-10.1%) IVB eyes. Disease-progression occurred in 9.2% (95% CI, 7.6%-11.2%) laser treated eyes, no (0%; 95% CI, 0.0-12.9%) IVB-only eyes. Vitreous hemorrhage occurred in 5.4% (95% CI: 4.1% - 7.0%) laser treated eyes, no IVB-only eyes.

Conclusions: Rates of complications are very low following ROP treatment with either laser or IVB. Of laser-treated eyes, 9% experienced disease progression despite treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Gil Binenbaum and David Morrison are site investigators for a randomized study that compares laser to ranibizumab injection, sponsored by Novartis.

References

    1. Quinn GE, Dobson V, Barr CC, et al. Visual acuity in infants after vitrectomy for severe retinopathy of prematurity. Ophthalmology. 1991;98:5–13. - PubMed
    1. Gilbert C, Fielder A, Gordillo L, et al. International NO-ROP Group Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate and high levels of development: implications for screening programs. Pediatrics. 2005;115:e518–25. - PubMed
    1. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367:2515–26. - PMC - PubMed
    1. White JE, Repka MX. Randomized comparison of diode laser photocoagulation versus cryotherapy for threshold retinopathy of prematurity: 3-year outcome. J Peditatr Ophthalmol Strabismus. 1997;34:83–7. - PubMed
    1. Clemett R, Darlow B. Results of screening low-birth-weight infants for retinopathy of prematurity. Curr Opin Ophthalmol. 1999;19:155–63. - PubMed

Publication types

MeSH terms